Clinical Trials
28 trialsNCT06120283 2026-05-27
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06492616 2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT07288359 2026-05-27
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT07604571 2026-05-27
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Novartis
Phase 1 Recruiting
NCT05472792 2026-05-26
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06953882 2026-05-26
SELECT
Yale University
Phase 2 Recruiting
NCT07054190 2026-05-26
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06075953 2026-05-22
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06930859 2026-05-22
ELEGANCE
Novartis
Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07349069 2026-05-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT07492641 2026-05-22
KANDELA-302
BeOne Medicines
Phase 3 Recruiting
NCT06143631 2026-05-20
PLUM
University of California, San Francisco
Phase 4 Recruiting
NCT07029399 2026-05-19
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 1 Recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT05512364 2026-05-15
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT07085767 2026-05-15
OPERA-02
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06979596 2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05774951 2026-05-08
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
NCT06507618 2026-05-08
POWER II
University of Virginia
Phase 3 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05872204 2026-05-05
ALEPRO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT06905301 2026-05-05
IMPULSE
Novartis
Recruiting
NCT06790693 2026-05-04
INAVO123
Hoffmann-La Roche
Phase 3 Recruiting
NCT06998407 2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting